Skip to content

A Multicentre Randomised Feasibility Study of Adjuvant Chemotherapy (CT) following Radical Primary Treatment for Transitional Cell Carcinoma (TCC) of the Bladder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN16638426
Enrollment
Unknown
Registered
2002-08-19
Start date
2000-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of bladder (advanced) Cancer Bladder

Interventions

Total Cystectomy or Radical RT +/- CT CT: Methotrexate 30 mg/m^2 (days 1, 15, 22) Vinblastine 3 mg/m^2 (days 2, 15, 22) Adriamycin 30 mg/m2 (day 2) Cisplatin 70 mg/m2 (day 2) every 28 days, maximum o

Sponsors

Northern Research and Development (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed invasive TCC of the bladder 2. Stage T2, T3a, T3b, T4a, N0 or T(any), N1/N2 3. Patient has undergone a complete resection at cystectomy or has received radical radiotherapy with curative intent 4. Fit enough to undergo combination chemotherapy 5. Creatinine clearance >60ml/min within 10 weeks of primary treatment 6. Haematological counts within 4 weeks before randomisation: White Blood Count (WBC) >3x10^9/l Platelets >100 x10^9/l Haemoglobin >10g/dl 7. Patient must be able to commence CT within 12 weeks of completion of primary treatment 8. Written informed consent

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration

Secondary

MeasureTime frame
Not provided at time of registration

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026